ARNO THERAPEUTICS INC

As of September 30, 2016, ARNO THERAPEUTICS INC carries a market capitalization of 22.49M, placing it among publicly traded companies globally. Its enterprise value stands at 20.37M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2016, ARNO THERAPEUTICS INC has 47.85M shares outstanding.

These figures are as of September 30, 2016.

As of September 30, 2016, ARNO THERAPEUTICS INC maintains a current ratio of 1.52, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -0.09, indicating conservative leverage, while an interest coverage ratio of -261.69 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2016. Return on assets (ROA) is negative at -990.47, reflecting losses generated across the asset base.

As of the close on September 4, 2026, ARNO THERAPEUTICS INC's stock has gained approximately 10000.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

These figures cover the twelve months ended September 30, 2016. EBITDA reached -11.06M, while operating income came in at -11.06M.

As of September 30, 2016, ARNO THERAPEUTICS INC holds 2.12M in cash and equivalents against 5,088.00 in total debt, resulting in a net debt position of -2.12M. Total book value stands at -5.71M, with working capital of 799,986.00 providing operational flexibility.

ARNO THERAPEUTICS INC produced -7.62M in operating cash flow over the twelve months ended September 30, 2016.

These figures cover the twelve months ended September 30, 2016. Free cash flow yield is negative at -44.57: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -42.77, meaning ARNO THERAPEUTICS INC raised more capital through share issuance and new debt than it returned via dividends and buybacks.

ARNO THERAPEUTICS INC's most recent stock split took place on October 30, 2013 with a 8:1 split ratio.